A Phase 1a/1b Study of LY3405105 Administered to Patients with Advanced Solid Tumors
Study of LY3405105 for Patients with Advanced Solid Tumors
Sponsor: Eli Lilly and Company
Enrolling: Male and Female Patients
IRB Number: AAAS1915
U.S. Govt. ID: NCT03770494
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: This study will explore an investigational drug called LY3405105. "Investigational" means that the drughas not been approved by the United States Food and Drug Administration (FDA). The purpose of thisstudy is to learn about: Whether LY3405105 besylate can help study participants with advanced solid tumors; The safety of LY3405105 besylate and any side effects study participants might have; How much LY3405105 besylate should be given to study participants. Cancers may include: breast cancer, lung cancer, soft tissue sarcoma, thyroid cancer, ovarian cancer, pancreatic cancer, stomach cancer, liver cancer, melanoma, and prostate cancer.
This study is closed
Gary Schwartz, MD
Do You Qualify?
Are you 18 years of age or older? Yes No
Do you have a solid tumor? Yes No
Does your cancer continue to grow even with treatment? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator